Full-Life Technologies, a global radiotherapeutics company, has announced a US$150 million financing package to accelerate its multiple clinical-stage assets and manufacturing capabilities.
The financing, completed on May 18, 2026, includes approximately US$110 million in Series D equity and US$40 million in debt financing, led by Vivo Capital and including participation from SK Biopharmaceuticals and other investors.
Proceeds will advance clinical programs such as [225Ac]-FL-020 for prostate cancer and [225Ac]-FL-261 for multiple solid tumors, and support the launch of GMP-grade 225Ac production at Full-Life's Belgium facility.
With this round, Full-Life has raised nearly US$350 million since its founding in 2021, solidifying its fully-integrated, clinical-stage global radiotherapeutics platform.
Regarding Quince’s reboot with a pulmonary drug, there is no current information available linking this phrase to Full-Life Technologies; the available news focuses on Full-Life’s recent funding and clinical and manufacturing expansion.
Sources:
TAE Technologies Raises $150 Million in Latest Funding Round
Full-Life Technologies acquiring Focus-X Therapeutics - Labiotech.eu
Full-Life Technologies Announces US$150 Million Financing to ...